Male Sexual Dysfunction Medical Services in China

Male Sexual Dysfunction (MSD) refers to a persistent or recurrent inability to attain and/or maintain an adequate penile erection (erectile dysfunction), ejaculate prematurely (premature ejaculation), experience delayed or absent ejaculation, or sustain sexual desire (hypoactive sexual desire disorder). It encompasses biopsychosocial disturbances affecting sexual response, satisfaction, and interpersonal intimacy. Pathogenesis is multifactorial: organic causes include vascular insufficiency (e.g., endothelial dysfunction from atherosclerosis), neurologic impairment (e.g., diabetic neuropathy, spinal cord injury), endocrine disorders (hypogonadism, hyperprolactinemia, thyroid dysfunction), pharmacologic effects (antidepressants, antihypertensives), and pelvic surgery or trauma. Psychogenic contributors—such as performance anxiety, depression, relationship conflict, and early negative sexual experiences—often coexist with or amplify organic factors. Epidemiologic studies indicate that approximately 30–50% of men aged 40–70 experience some degree of erectile dysfunction, with prevalence rising steadily with age; premature ejaculation affects an estimated 20–30% of adult men globally. Risk factors span modifiable and non-modifiable domains: cardiovascular disease, metabolic syndrome, obesity, smoking, excessive alcohol use, sedentary lifestyle, untreated depression or anxiety, chronic stress, sleep apnea, and aging. Importantly, MSD is strongly associated with underlying systemic pathology—serving as an early sentinel for cardiovascular disease—and warrants comprehensive medical evaluation beyond symptom management. The quality-of-life impact is profound: men report diminished self-esteem, increased psychological distress, reduced work productivity, strained intimate relationships, and higher rates of marital dissatisfaction or separation. Partners often experience decreased sexual satisfaction, emotional distance, and secondary anxiety—highlighting the dyadic nature of sexual health. Untreated MSD correlates with elevated risks of depression, social withdrawal, and reduced overall life satisfaction. Early diagnosis and integrated care—spanning urology, endocrinology, psychology, and reproductive medicine—are essential to address both physiological mechanisms and psychosocial consequences. In the Department of Reproductive Medicine, MSD evaluation emphasizes fertility implications (e.g., ejaculatory failure impairing conception), hormonal profiling (testosterone, prolactin, LH, FSH, SHBG), vascular assessment, and personalized behavioral interventions alongside pharmacotherapy.

Male sexual dysfunction (MSD) encompasses a spectrum of disorders affecting sexual desire, arousal, erection, ejaculation, and orgasm. It is broadly categorized into hypoactive sexual desire disorder (HSDD), erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation (DE), and anorgasmia. Etiology is typically multifactorial, involving interplay among organic, psychological, behavioral, genetic, and environmental determinants.

Common organic causes include vascular insufficiency—often secondary to atherosclerosis, hypertension, or diabetes mellitus—which impairs nitric oxide–mediated smooth muscle relaxation in the corpora cavernosa. Neurological disorders such as multiple sclerosis, Parkinson disease, spinal cord injury, diabetic neuropathy, and post-prostatectomy nerve damage disrupt central or peripheral neural pathways essential for sexual response. Endocrine abnormalities—including hypogonadism (low testosterone), hyperprolactinemia, thyroid dysfunction (both hypo- and hyperthyroidism), and cortisol excess in Cushing syndrome—alter libido, erectile physiology, and ejaculatory control. Structural penile pathology (e.g., Peyronie disease), pelvic floor myofascial dysfunction, and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) also contribute significantly.

Psychological triggers are prevalent, particularly in younger men without comorbidities. Performance anxiety, depression, generalized anxiety disorder, post-traumatic stress disorder (PTSD), relationship conflict, sexual trauma history, and body image concerns can initiate or perpetuate MSD via sympathetic overactivation and inhibition of parasympathetic outflow. Cognitive distortions (e.g., catastrophic misinterpretation of transient erectile difficulty) often sustain dysfunction even after resolution of initial organic triggers.

Key modifiable risk factors include advancing age (associated with declining testosterone, endothelial dysfunction, and cumulative vascular damage), obesity (driving inflammation, insulin resistance, aromatase-mediated estrogen excess, and reduced SHBG), smoking (inducing endothelial injury and microvascular vasoconstriction), excessive alcohol intake (acute CNS depression; chronic hepatic impairment and testicular toxicity), and sedentary lifestyle (exacerbating metabolic syndrome and reducing nitric oxide bioavailability). Metabolic syndrome—defined by abdominal obesity, dyslipidemia, hypertension, and impaired fasting glucose—is strongly correlated with ED severity and progression. Certain medications act as iatrogenic triggers: selective serotonin reuptake inhibitors (SSRIs), antipsychotics (e.g., risperidone), alpha-blockers, beta-blockers, 5-alpha-reductase inhibitors (e.g., finasteride), and opioid analgesics.

Genetic factors confer susceptibility rather than deterministic causation. Polymorphisms in genes regulating nitric oxide synthase (NOS3), phosphodiesterase type 5 (PDE5), and androgen receptor (AR) CAG repeat length have been associated with altered erectile response and testosterone sensitivity. Variants in dopamine receptor (DRD2) and serotonin transporter (SLC6A4) genes correlate with ejaculatory latency and reward-processing deficits in PE and HSDD. Familial clustering of ED suggests heritable components in endothelial function, autonomic regulation, and hypothalamic-pituitary-gonadal axis set points; however, no single-gene disorder accounts for most cases.

Environmental exposures exert both direct and epigenetic influences. Endocrine-disrupting chemicals (EDCs)—including bisphenol A (BPA), phthalates, organochlorine pesticides (e.g., DDT metabolites), and perfluoroalkyl substances (PFAS)—interfere with steroidogenesis, androgen receptor signaling, and Leydig cell function, potentially contributing to declining sperm counts and concomitant sexual dysfunction. Occupational hazards such as prolonged bicycling (causing pudendal nerve compression and perineal hypoxia), exposure to heavy metals (lead, cadmium), and chronic shift work (disrupting circadian melatonin and testosterone rhythms) are documented contributors. Psychosocial environmental stressors—including socioeconomic disadvantage, occupational burnout, social isolation, and inadequate sex education—compound biological vulnerabilities through chronic HPA-axis activation and allostatic load.

In clinical practice, comprehensive evaluation requires detailed history (including temporal onset, situational context, medication review, psychosocial stressors), physical examination (focusing on secondary sexual characteristics, genital anatomy, neurological screening), and targeted investigations (e.g., morning total testosterone, prolactin, lipid panel, HbA1c, penile Doppler ultrasound if indicated). Recognition of this complex etiologic landscape underscores the necessity for integrated, patient-centered management spanning urology, endocrinology, psychiatry, and behavioral medicine.

Male sexual dysfunction (MSD) encompasses a heterogeneous group of disorders affecting one or more phases of the male sexual response cycle—desire, arousal, erection, orgasm, and resolution—and is commonly evaluated in reproductive medicine departments due to its profound implications for fertility, psychological well-being, and overall quality of life. Early symptoms are often subtle and may be overlooked by patients and clinicians alike. These include diminished spontaneous libido, reduced frequency of nocturnal penile tumescence (NPT), delayed or inconsistent morning erections, increased latency to achieve erection during sexual activity, decreased penile rigidity despite subjective arousal, and mild ejaculatory hesitation. Patients may report a growing sense of effort or mental strain required to initiate or maintain sexual interest or response—a phenomenon termed 'erectile fragility.' Importantly, early manifestations frequently co-occur with non-specific systemic signs such as persistent fatigue, unexplained mood lability, declining exercise tolerance, or subtle metabolic changes (e.g., rising fasting glucose or waist circumference), reflecting underlying endocrine, vascular, or neuropsychological contributors.

Typical symptoms represent the clinically apparent, reproducible disturbances that prompt formal evaluation. Erectile dysfunction (ED) is the most prevalent presentation, defined as the recurrent or persistent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance over a minimum duration of three months. It manifests as partial or complete failure of rigidity, premature detumescence (<10 minutes), or inability to penetrate or sustain intercourse. Hypoactive sexual desire disorder (HSDD) presents as persistently deficient or absent sexual fantasies and desire for sexual activity, not attributable solely to situational stressors or relationship conflict. Delayed ejaculation (DE) is characterized by marked delay or inability to achieve orgasm and ejaculation despite adequate stimulation and desire; it may involve prolonged latency (>25–30 minutes), anorgasmia, or absent emission. Premature ejaculation (PE), though often considered a separate entity, falls within MSD when it is lifelong, generalized, and associated with distress or interpersonal difficulty—defined as ejaculation occurring within approximately one minute of vaginal penetration (lifelong) or a clinically significant reduction in ejaculatory latency (acquired), accompanied by perceived lack of control and negative personal consequences. Retrograde ejaculation—where semen enters the bladder rather than exiting via the urethra—is typified by cloudy post-ejaculatory urine and low-volume or dry orgasm, commonly following prostate surgery, diabetes, or alpha-adrenergic antagonist use.

Accompanying symptoms provide critical diagnostic context. Psychological features include anticipatory anxiety, performance-related avoidance, diminished self-esteem, irritability, and symptoms of depression or generalized anxiety disorder. Autonomic and somatic comorbidities frequently coexist: orthostatic dizziness, abnormal sweating patterns, or gastrointestinal dysmotility may suggest autonomic neuropathy (e.g., in diabetes or Parkinson disease). Lower urinary tract symptoms (LUTS)—such as weak stream, hesitancy, nocturia, or urgency—often accompany benign prostatic hyperplasia or chronic prostatitis and may contribute to sexual inhibition or pelvic floor hypertonicity. Metabolic stigmata—including central obesity, acanthosis nigricans, or hypertension—are red flags for metabolic syndrome and endothelial dysfunction. Hormonal correlates include decreased muscle mass, increased adiposity, gynecomastia, reduced facial or axillary hair, and osteopenia—suggesting late-onset hypogonadism. Sleep disturbances, particularly untreated obstructive sleep apnea, correlate strongly with ED and low testosterone.

Complications extend beyond sexual dissatisfaction. Infertility arises directly from ejaculatory disorders (e.g., anejaculation, retrograde ejaculation) or indirectly via reduced coital frequency and suboptimal timing relative to ovulation. Psychosocial sequelae include intimate relationship strain, marital discord, social withdrawal, and increased risk of major depressive disorder and suicidal ideation. Cardiovascular morbidity is a critical long-term complication: ED is an independent predictor of future coronary artery disease, stroke, and all-cause mortality—often preceding overt cardiovascular events by 2–5 years due to shared pathophysiology involving endothelial injury, inflammation, and atherosclerosis. Chronic MSD may also accelerate metabolic decompensation, worsen glycemic control in diabetics, and impair adherence to preventive health behaviors.

Diagnosis relies on a structured, multidimensional assessment. A detailed sexual history—using validated instruments such as the International Index of Erectile Function (IIEF-5), Premature Ejaculation Profile (PEP), or Decreased Sexual Desire Screener (DSDS)—is foundational. Physical examination includes BMI, blood pressure, secondary sex characteristics, testicular volume (orchidometer), penile anatomy (e.g., Peyronie plaques), and digital rectal exam to assess prostate and sphincter tone. Laboratory evaluation mandates fasting glucose, HbA1c, lipid panel, total and free testosterone (drawn between 7–10 a.m.), prolactin, TSH, and optionally estradiol and SHBG. Nocturnal penile tumescence testing (RigiScan®) objectively quantifies erectile capacity during sleep, distinguishing psychogenic from organic etiologies. Doppler ultrasonography after intracavernosal injection assesses arterial inflow, venous leakage, and structural abnormalities. In select cases, dynamic infusion cavernosometry/cavernosography, neurophysiological testing (bulbocavernosus reflex latency), or pelvic MRI may be indicated.

Differential diagnosis requires careful exclusion of mimics. Organic causes include vascular (atherosclerosis, pelvic trauma), neurologic (multiple sclerosis, spinal cord injury, diabetic neuropathy), endocrine (hypogonadism, hyperprolactinemia, thyroid dysfunction), iatrogenic (SSRIs, antihypertensives, 5-alpha reductase inhibitors), and structural (Peyronie disease, severe phimosis). Psychogenic etiologies—performance anxiety, depression, unresolved trauma, or partner-related conflict—typically preserve nocturnal and morning erections and exhibit situational variability. Mixed etiology is the rule rather than exception, especially in men >50 years. Conditions requiring distinction include normal aging-related decline (gradual, non-distressing), situational sexual difficulties (context-dependent, transient), sexual aversion disorder (intense fear/avoidance), and paraphilic disorders. Importantly, 'sexual dysfunction' must be differentiated from consensual variations in sexual expression, low-frequency desire in stable relationships, or cultural/religious norms—not all deviations from statistical norms constitute pathology. Accurate diagnosis hinges on integrating biopsychosocial data, recognizing that MSD is rarely isolated but rather a sentinel marker of systemic health.

Male sexual dysfunction (MSD) encompasses a spectrum of conditions—including erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation, anejaculation, and hypoactive sexual desire disorder—that impair sexual performance, satisfaction, or reproductive function. In the Department of Reproductive Medicine, evaluation begins with a comprehensive biopsychosocial assessment: detailed sexual history, physical examination (including genital inspection, neurological screening, and cardiovascular risk profiling), hormonal profiling (total and free testosterone, prolactin, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone), and validated questionnaires (e.g., International Index of Erectile Function-5, Premature Ejaculation Profile). Additional diagnostics may include nocturnal penile tumescence testing, intracavernosal injection pharmacotesting, duplex Doppler ultrasonography, and semen analysis when fertility concerns coexist.

Conservative treatment forms the cornerstone of initial management. Lifestyle optimization is evidence-based and first-line: sustained weight loss (>5% body weight) in overweight/obese men improves endothelial function and testosterone levels; aerobic exercise ≥150 minutes/week enhances nitric oxide bioavailability and reduces systemic inflammation; smoking cessation and alcohol moderation directly improve cavernosal smooth muscle relaxation and microvascular integrity. Psychological interventions—particularly cognitive-behavioral therapy (CBT) and mindfulness-based sex therapy—are indicated for performance anxiety, relationship discord, or depression-related sexual inhibition. Pelvic floor muscle training (PFMT), guided by urological physiotherapists, demonstrates efficacy in both PE (via improved ejaculatory control) and mild ED (by enhancing bulbocavernosus reflex and veno-occlusive competence). Nutritional counseling emphasizes Mediterranean-pattern diets rich in nitrates (leafy greens), antioxidants (berries, nuts), and omega-3 fatty acids (fatty fish), while discouraging ultra-processed foods and excessive saturated fats.

Pharmacotherapy is stratified by etiology and severity. For organic ED, phosphodiesterase type 5 inhibitors (PDE5is)—sildenafil, tadalafil, vardenafil, and avanafil—are first-line. Tadalafil’s 36-hour half-life supports flexible dosing (on-demand or daily low-dose 2.5–5 mg), particularly beneficial in men with concomitant lower urinary tract symptoms. Intracavernosal alprostadil injections remain highly effective for neurogenic or post-prostatectomy ED unresponsive to oral agents, with >80% success rates in rigorous trials. Topical alprostadil cream (Vitaros®) offers a non-invasive alternative, though absorption variability limits consistency. For PE, on-demand dapoxetine (a short-acting selective serotonin reuptake inhibitor) is FDA- and EMA-approved and significantly increases intravaginal ejaculatory latency time (IELT); daily SSRIs (e.g., paroxetine, sertraline) are reserved for lifelong PE with comorbid depression. Off-label topical anesthetics (e.g., lidocaine-prilocaine cream) require careful application to avoid partner numbness and must be washed prior to intercourse. Hormonal therapy is strictly indicated only in confirmed hypogonadism (total testosterone <8 nmol/L with symptomatic deficiency); transdermal gels or intramuscular testosterone undecanoate restore libido and energy but require monitoring of hematocrit, prostate-specific antigen (PSA), and sleep apnea symptoms.

Surgical intervention is considered only after failure of conservative and medical therapies. Penile prosthesis implantation—either malleable (semi-rigid) or inflatable (two- or three-piece)—offers >95% patient and partner satisfaction rates and durable restoration of rigidity. Modern inflatable devices feature antibiotic-coated cylinders and refined hydraulic mechanisms minimizing mechanical failure (<5% at 5 years). Vascular surgery (e.g., arterial bypass for young traumatic arterial insufficiency) is exceedingly rare and limited to highly selected cases (<1% of ED referrals) due to poor long-term patency. Microsurgical sperm retrieval (e.g., micro-TESE) is not a treatment for MSD per se but is integrated when MSD coexists with obstructive or non-obstructive azoospermia requiring assisted reproductive technology.

Treatment in China offers distinct advantages within the Reproductive Medicine framework. First, integrated multidisciplinary teams—comprising reproductive endocrinologists, andrologists, clinical psychologists, pelvic floor therapists, and traditional Chinese medicine (TCM) practitioners—enable seamless coordination. While Western pharmacotherapy is standard, evidence-informed TCM adjuncts (e.g., Bushen Yiqi decoction for kidney-yang deficiency patterns) are offered where robust RCT data support synergistic effects on endothelial function and oxidative stress. Second, China’s national health infrastructure ensures rapid access to advanced diagnostics: high-resolution penile Doppler ultrasound with quantitative flow metrics, automated semen morphology analysis (strict criteria), and genetic testing (e.g., Y-chromosome microdeletion screening) are widely available in tier-3 hospitals. Third, cost-effectiveness is notable: generic PDE5is and domestically manufactured prostheses reduce out-of-pocket expenses by 40–60% versus Western markets, without compromising quality standards (CFDA/NMPA certification). Fourth, digital health integration—including AI-assisted symptom tracking apps linked to hospital EMRs and tele-rehabilitation for PFMT—enhances adherence and longitudinal monitoring.

Post-treatment recovery requires structured, individualized guidance. Patients initiating PDE5is should be counseled on optimal timing (e.g., sildenafil 60 minutes pre-intercourse, avoiding high-fat meals), realistic expectations (success rates ~70% in mild-moderate ED), and safety parameters (contraindication with nitrates, caution in uncontrolled hypertension). After prosthesis surgery, strict wound care, abstinence for 6 weeks, and graded device activation under clinician supervision prevent complications. All patients receive written sexual rehabilitation protocols: graded exposure exercises for anxiety reduction, sensate focus techniques to decouple performance pressure from intimacy, and scheduled ‘non-goal-oriented’ touch sessions. Follow-up intervals are protocol-driven: 2 weeks post-initiation of any new therapy, then monthly for 3 months, transitioning to quarterly for stable responders. Long-term surveillance includes annual testosterone and PSA checks for hormonal therapy recipients, and duplex ultrasound at 12 months post-prosthesis to assess corporal integrity. Crucially, partners are actively engaged in counseling—joint sessions address communication barriers, shared goal-setting, and mutual understanding of physiological constraints—recognizing that MSD is a dyadic, not merely individual, health concern. With this comprehensive, patient-centered, and evidence-grounded approach, over 85% of men with MSD achieve clinically meaningful improvement in sexual function and quality of life within 6 months.